HeartSciences (NASDAQ:HSCS) Issues Quarterly Earnings Results

HeartSciences (NASDAQ:HSCS) posted its earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14), FiscalAI reports. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million.

HeartSciences Stock Up 4.4%

Shares of NASDAQ HSCS traded up $0.15 during trading hours on Monday, hitting $3.54. 76,855 shares of the stock were exchanged, compared to its average volume of 848,374. HeartSciences has a 12 month low of $1.63 and a 12 month high of $4.35. The firm has a fifty day moving average price of $2.67 and a 200-day moving average price of $2.38. The company has a market cap of $13.81 million, a PE ratio of -0.90 and a beta of 1.85.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of HeartSciences to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, HeartSciences has an average rating of “Hold” and a consensus target price of $8.00.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.